Opendata, web and dolomites

HELMO

Cardiovascular Diseases Diagnoses by means of Smart Remote Monitoring System based on known Heart Activity Biomarkers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HELMO project word cloud

Explore the words cloud of the HELMO project. It provides you a very rough idea of what is the project "HELMO" about.

breath    consciousness    deaths    validating    accounting    discharged    million    12    critical    biomarkers    suffer    population    xeos    almost    spurred    risk    oxygen    leads    primary    bill    demand    economic    temperature    diseases    sweat    caused    group    nearly    highs    movement    pressure    interventions    identification    attack    detection    vascular    death    14    hospitalization    inpatients    hefty    blood    remotely    vital    invasive    fatal    revenues    location    lack    patients    heart    medical    accounts    market    innovative    chronical    experiment    hospitals    mean    diagnoses    moments    cvd    ecg    remote    clinically    47    assistance    special    196    calories    dying    helmo    23    rates    people    body    economy    stroke    billion    clear    commercialization    global    gt    recurrences    2022    survivors    launched    grow    cardiovascular    treatment    2030    monitoring    solutions    life    17    half    event    monitor    device    cardio    alerts    risks    clinicians    quality    designed    prioritized    care    saturation   

Project "HELMO" data sheet

The following table provides information about the project.

Coordinator
XEOS.IT SRL 

Organization address
address: VIA ENZO FERRARI 16/18 PALAZZO BETA
city: RONCADELLE BS
postcode: 25030
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://franco.boldi
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    XEOS.IT SRL IT (RONCADELLE BS) coordinator 50˙000.00

Map

 Project objective

Cardiovascular Diseases are the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to >23.6 million by 2030. In Europe, it accounts for over 4 million deaths each year which means nearly half 47% of all deaths. Overall CVD is estimated to cost the EU economy almost €196 billion a year. It is clear that there is an economic demand to implement cost effective measures to early diagnoses of CVD and detection of highs risks to suffer a fatal event. The WHO has prioritized these interventions as: early identification of people at high risk in primary care and monitoring of survivors of a heart attack or stroke which are at high risk of recurrences or dying from them. Indeed, spurred by the hefty bill and lack of resources, Hospitals are continuously looking for new solutions to allow them to discharged chronical inpatients who can be remotely monitoring improving its quality of life and providing tailored treatment. The project HELMO aims at developing and clinically validating a no-invasive remote monitoring medical device for the early diagnoses of cardio vascular diseases (CVD) and to provide assistance before fatal consequences, even death. The product will be launched to the market as an innovative system able to monitor remotely 10 vital parameters which are well known biomarkers of CVD diseases: ECG – 12 leads ECG -, heart and breath rates, blood pressure, movement, oxygen saturation, body temperature, sweat, calories, location. This device, designed by all population including special needs group, will provide alerts both patients and clinicians at critical moments which can lead to loss of consciousness and death. As a result, the number of hospitalization caused by CVD and eventually the deaths will experiment a significant reduction. HELMO is a non-invasive medical device based on the monitoring of CVD biomarkers which commercialization will mean €14.4 M revenues for XEOS by 2022.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HELMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HELMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More